XML 27 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
Share-Based Compensation (Details) (USD $)
 6 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Mar. 31, 2012
Stock Options [Member]
Mar. 31, 2011
Stock Options [Member]
Mar. 31, 2012
Stock Options [Member]
Executive officers [Member]
Mar. 31, 2012
Stock Options [Member]
Directors [Member]
Mar. 31, 2011
Stock Options [Member]
Directors [Member]
Mar. 31, 2011
Stock Options [Member]
Executive officers and employees [Member]
Mar. 31, 2012
Restricted Stock [Member]
Jun. 30, 2012
Performance-Based Restricted Stock Awards [Member]
Jun. 30, 2012
Performance-Based Restricted Stock Awards [Member]
Dec. 31, 2011
Performance-Based Restricted Stock Awards [Member]
Stock Options [Abstract]                        
Options granted (in shares)     690,000 692,500                
Vesting period         4 years 2 years 2 years 4 years        
Options, grant date fair value (in dollars per share)         $ 2.1 $ 1.35 $ 3.15 $ 3.46        
Allocated share-based compensation expense     $ 1,373,000 $ 2,375,000         $ 654,000      
Restricted Stock Award [Abstract]                        
Restricted stock issued during period (in shares)                 190,000      
Performance Based Restricted Stock Awards [Abstract]                        
Performance-based restricted stock awards - description of terms                     The awards provide certain employees until December 31, 2012 to achieve certain performance goals established by the Compensation Committee. The performance goals are weighted based on the following achievements: entering into a major collaboration for development and/or commercialization of the Company's products (40%), obtaining certain FDA clearance or approvals, which include FDA approval for and initiation of the ATHENA feasibility trial in chronic myocardial ischemia (40%), obtaining CE mark for certain products (15%), and achieving a targeted revenue increase for the fiscal year ended December 31, 2012 (5%). To the extent that any of the performance goals are partially achieved, the Compensation Committee maintains the discretion to continue the vesting of all or a portion of the awards following December 31, 2012. Once earned, the awards will remain unvested until January 10, 2014. Termination of employment prior to vesting will result in the forfeiture of the awards. The awards provide certain employees until January 1, 2012 to achieve certain performance goals established by the Compensation Committee. Effective January 2012, the outstanding awards were terminated in their entirety based upon the decision by the Compensation Committee that performance criteria had not been met as of January 1, 2012. No compensation expense was recognized related to these awards.
Share-based compensation expense $ 1,977,000 $ 1,721,000               $ 49,000 $ 49,000  
Performance-Based Restricted Stock Awards [Roll Forward]                        
Outstanding (in shares)                     246,225  
Granted (in shares)                     276,375  
Vested (in shares)                     0  
Cancelled/forfeited (in shares)                     (261,300)  
Outstanding (in shares)                   261,300 261,300 246,225
Vested (in shares)                     0  
Performance-Based Restricted Stock Awards, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]                        
Outstanding - Weighted Average Grant Date Fair Value (in dollars per share)                     $ 5.82  
Granted - Weighted Average Grant Date Fair Value (in dollars per share)                     $ 3.44  
Cancelled/forfeited - Weighted Average Grant Date Fair Value (in dollars per share)                     $ 5.68  
Outstanding - Weighted Average Grant Date Fair Value (in dollars per share)                   $ 3.44 $ 3.44 $ 5.82